譽衡藥業(002437.SZ):控股股東終止協議轉讓15%股份
格隆匯 7 月 6日丨譽衡藥業(002437.SZ)公佈,2020年7月6日,公司收到控股股東哈爾濱譽衡集團有限公司(“譽衡集團”)通知,獲悉譽衡集團與蘇州譽通衡投資合夥企業(有限合夥)、蘇州翼樸蘇榆股權投資合夥企業(有限合夥)、博裕三期(上海)股權投資合夥企業(有限合夥)(“交易對方”)已終止2018年8月17日簽署的《股份轉讓協議》及相關協議。
2018年8月17日,譽衡集團與各交易對方分別簽訂《股份轉讓協議》,擬將其持有的公司約3.3億股股份(合計佔公司股份總數的15.00%)分別轉讓給各交易對方,交易對方各自的受讓比例均為5.00%。
因譽衡集團債務違約及所持公司股份被司法凍結,此次股份轉讓事宜未能成功實施,經譽衡集團與交易對方友好協商,各方於2020年7月6日分別簽署了《終止協議》,同意終止2018年8月17日簽署的《股份轉讓協議》及相關協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.